Treatment of Multiple Sclerosis with Peptide-Coupled Red Blood Cells Induces Antigen-Specific T Regulatory Cells

Researchers developed a therapy based on autologous red blood cells as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, Phase Ib clinical trial with clinical, imaging, and mechanistic readouts.